Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (PRVCF) is an innovative health sciences company developing preventive and curative therapies through advanced biotechnology research. This page serves as the definitive source for verified news and official updates about the company's scientific advancements and corporate developments.
Investors and researchers will find timely updates on PRVCF's progress across multiple therapeutic programs, including its nature-identical peptide research, Sol-Gel drug delivery platform, and non-addictive pain management solutions. Our curated news feed ensures stakeholders stay informed about material events including clinical trial milestones, intellectual property filings, and strategic partnership announcements.
The news collection focuses on three key areas: Research Breakthroughs (gene therapy progress, preclinical study results), Operational Updates (regulatory filings, financial disclosures), and Strategic Developments (collaborations, patent grants). Each update is verified against original source materials to ensure accuracy.
Bookmark this page for streamlined access to PRVCF's latest advancements in preventive health sciences. For comprehensive analysis of how these developments may impact long-term research trajectories, consider subscribing to our investment research updates.
PreveCeutical Medical provides an update on its Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC) due to a delay in filing its audited annual financial statements for 2023. The delay was caused by a lack of funds, but the company has now engaged Smythe LLP and expects to file the statements by June 28, 2024.
The company also completed the first tranche of a non-brokered private placement, raising $115,000 through the sale of 4,600,000 units at $0.025 per unit. The funds will be used for working capital, including audit fees. Until the filings are complete, the company will issue bi-weekly updates. Trading in the company's shares will continue for the general public, but insiders and officers are restricted. The company is not subject to insolvency proceedings.
PreveCeutical Medical has provided an update on the Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's delay in filing its annual financial statements for the year ended December 31, 2023. The delay was caused by a lack of funds to engage auditors. The company has now engaged Smythe LLP and expects to file the required documents by June 28, 2024. During this period, the CEO, CFO, and certain other officers cannot trade in the company's shares. The general public can continue to trade them. PreveCeutical also plans a private placement to raise up to $250,000 for working capital, including audit fees.
PreveCeutical Medical Inc. announces a Management Cease Trade Order due to missing the deadline for filing annual financial statements. The Company applied for a MCTO as a result of a lack of funds preventing completion of the audit on time. PreveCeutical expects to file the Annual Filings by June 28, 2024, and will provide bi-weekly default status reports until then. Additionally, the Company plans a private placement to raise $250,000 for working capital purposes.
FAQ
What is the current stock price of Preveceutical (PRVCF)?
What is the market cap of Preveceutical (PRVCF)?
